Baker Avenue Asset Management’s CareDx CDNA Stock Holding History

Baker Avenue Asset Management’s Portfolio CDNA Stock Details CDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-42	Closed	-$479	–	1634
2022 Q4	$479	Buy	+42	New	+$622	﹤0.01%	1339

Other funds holding CDNA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

Baker Avenue Asset Management's CDNA Position: Q1 2023 in Review

Baker Avenue Asset Management sold out of CareDx (CDNA) in Q1 2023, closing a stake of 42 shares — an estimated $479 sold.

Baker Avenue Asset Management first reported a position in CDNA in Q4 2022 and held it in 1 quarter. The position peaked at $479 in Q4 2022. 156 funds tracked by Wall St. Rank hold CDNA as of Q1 2023.

Baker Avenue Asset Management reported no remaining CareDx position as of Q1 2023 after selling out during the quarter.
Baker Avenue Asset Management sold 42 CareDx shares in Q1 2023, an estimated $479.
Baker Avenue Asset Management first reported a position in CareDx in Q4 2022 and held it in 1 quarter.
Baker Avenue Asset Management's CareDx position peaked at $479 in Q4 2022.
156 funds tracked by Wall St. Rank held CareDx as of Q1 2023.

Based on Baker Avenue Asset Management's 13F filing for Q1 2023, filed 16 May 2023.